JP2020506244A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020506244A5 JP2020506244A5 JP2019563698A JP2019563698A JP2020506244A5 JP 2020506244 A5 JP2020506244 A5 JP 2020506244A5 JP 2019563698 A JP2019563698 A JP 2019563698A JP 2019563698 A JP2019563698 A JP 2019563698A JP 2020506244 A5 JP2020506244 A5 JP 2020506244A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- cancer
- optionally substituted
- groups
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 31
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 125000005843 halogen group Chemical group 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 11
- 125000000304 alkynyl group Chemical group 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 10
- -1 R a1 Chemical group 0.000 claims 9
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 8
- 125000001153 fluoro group Chemical group F* 0.000 claims 7
- 239000002904 solvent Substances 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 208000005243 Chondrosarcoma Diseases 0.000 claims 3
- 201000008808 Fibrosarcoma Diseases 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 3
- 239000000969 carrier Substances 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 201000005262 Chondroma Diseases 0.000 claims 2
- 206010024612 Lipoma Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000000035 Osteochondroma Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 206010046431 Urethral cancer Diseases 0.000 claims 2
- 206010046458 Urethral neoplasms Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 229910001413 alkali metal ion Inorganic materials 0.000 claims 2
- 150000001345 alkine derivatives Chemical group 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 206010016629 fibroma Diseases 0.000 claims 2
- 201000011066 hemangioma Diseases 0.000 claims 2
- 230000002489 hematologic effect Effects 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 229910001507 metal halide Inorganic materials 0.000 claims 2
- 150000005309 metal halides Chemical class 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000003444 phase transfer catalyst Substances 0.000 claims 2
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- QCZNWFTWNFCLLN-UHFFFAOYSA-N 3-nitro-2-piperidin-3-ylsulfinylpyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1S(=O)C1CNCCC1 QCZNWFTWNFCLLN-UHFFFAOYSA-N 0.000 claims 1
- SDRQVOWUQCVPEI-UHFFFAOYSA-N 3-nitro-2-piperidin-4-ylsulfinylpyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1S(=O)C1CCNCC1 SDRQVOWUQCVPEI-UHFFFAOYSA-N 0.000 claims 1
- MIYVPOMPYOUYBW-UHFFFAOYSA-N 3-nitro-2-piperidin-4-ylsulfonylpyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1S(=O)(=O)C1CCNCC1 MIYVPOMPYOUYBW-UHFFFAOYSA-N 0.000 claims 1
- HABXRSUEFGTSOY-UHFFFAOYSA-N 3-nitro-2-pyrrolidin-3-ylsulfinylpyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1S(=O)C1CNCC1 HABXRSUEFGTSOY-UHFFFAOYSA-N 0.000 claims 1
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 claims 1
- 206010062805 Dysplastic naevus Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000007569 Giant Cell Tumors Diseases 0.000 claims 1
- 208000002927 Hamartoma Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 206010019629 Hepatic adenoma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 239000002841 Lewis acid Substances 0.000 claims 1
- 208000002404 Liver Cell Adenoma Diseases 0.000 claims 1
- 206010027145 Melanocytic naevus Diseases 0.000 claims 1
- 208000015021 Meningeal Neoplasms Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000009905 Neurofibromatoses Diseases 0.000 claims 1
- 208000007256 Nevus Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005678 Rhabdomyoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000032383 Soft tissue cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 206010043276 Teratoma Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 201000006491 bone marrow cancer Diseases 0.000 claims 1
- 201000002143 bronchus adenoma Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000013066 combination product Substances 0.000 claims 1
- 229940127555 combination product Drugs 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000010255 female reproductive organ cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000006359 hepatoblastoma Diseases 0.000 claims 1
- 201000002735 hepatocellular adenoma Diseases 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 150000007517 lewis acids Chemical class 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000022006 malignant tumor of meninges Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000009091 myxoma Diseases 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 201000004931 neurofibromatosis Diseases 0.000 claims 1
- 208000004649 neutrophil actin dysfunction Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 201000011096 spinal cancer Diseases 0.000 claims 1
- 208000014618 spinal cord cancer Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 1
- ZVQSMOIZBTZVEA-UHFFFAOYSA-N tert-butyl 3-(3-nitropyridin-2-yl)sulfinylpiperidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC1S(=O)C1=NC=CC=C1[N+]([O-])=O ZVQSMOIZBTZVEA-UHFFFAOYSA-N 0.000 claims 1
- HFWDMADXQUCWRL-UHFFFAOYSA-N tert-butyl 3-(3-nitropyridin-2-yl)sulfinylpyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC1S(=O)C1=NC=CC=C1[N+]([O-])=O HFWDMADXQUCWRL-UHFFFAOYSA-N 0.000 claims 1
- UCCOLLPQIPXMKA-UHFFFAOYSA-N tert-butyl 3-(3-nitropyridin-2-yl)sulfonylpiperidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC1S(=O)(=O)C1=NC=CC=C1[N+]([O-])=O UCCOLLPQIPXMKA-UHFFFAOYSA-N 0.000 claims 1
- UWHJLCANHJRLOR-UHFFFAOYSA-N tert-butyl 3-(3-nitropyridin-2-yl)sulfonylpyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC1S(=O)(=O)C1=NC=CC=C1[N+]([O-])=O UWHJLCANHJRLOR-UHFFFAOYSA-N 0.000 claims 1
- BQKBFONGUFRMBD-UHFFFAOYSA-N tert-butyl 4-(3-nitropyridin-2-yl)sulfinylpiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1S(=O)C1=NC=CC=C1[N+]([O-])=O BQKBFONGUFRMBD-UHFFFAOYSA-N 0.000 claims 1
- KWEADHKVLWRLQX-UHFFFAOYSA-N tert-butyl 4-(3-nitropyridin-2-yl)sulfonylpiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1S(=O)(=O)C1=NC=CC=C1[N+]([O-])=O KWEADHKVLWRLQX-UHFFFAOYSA-N 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 0 Cc1c(*I)nc(*)c([N+]([O-])=O)c1* Chemical compound Cc1c(*I)nc(*)c([N+]([O-])=O)c1* 0.000 description 3
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762455644P | 2017-02-07 | 2017-02-07 | |
| US62/455,644 | 2017-02-07 | ||
| US201762594784P | 2017-12-05 | 2017-12-05 | |
| US62/594,784 | 2017-12-05 | ||
| PCT/GB2018/050345 WO2018146471A1 (en) | 2017-02-07 | 2018-02-07 | Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020506244A JP2020506244A (ja) | 2020-02-27 |
| JP2020506244A5 true JP2020506244A5 (https=) | 2021-03-04 |
Family
ID=61231287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563698A Pending JP2020506244A (ja) | 2017-02-07 | 2018-02-07 | ヘテロシクリルスルホニル置換ピリジンおよび癌の治療におけるそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11168069B2 (https=) |
| EP (1) | EP3580209A1 (https=) |
| JP (1) | JP2020506244A (https=) |
| KR (1) | KR20190115012A (https=) |
| CN (1) | CN110382480A (https=) |
| AU (1) | AU2018218521C1 (https=) |
| BR (1) | BR112019016233A2 (https=) |
| CA (1) | CA3051538A1 (https=) |
| MA (1) | MA47452A (https=) |
| MX (1) | MX389800B (https=) |
| WO (1) | WO2018146471A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201514021D0 (en) | 2015-08-07 | 2015-09-23 | Arner Elias Set Jeno | Novel Pyridines and their use in the treatment of cancer |
| JP2020507625A (ja) | 2017-02-07 | 2020-03-12 | オブリーク セラピューティクス アーベー | ヘテロアリールスルホニル置換ピリジンおよび癌の治療におけるそれらの使用 |
| CA3051539A1 (en) | 2017-02-07 | 2018-08-16 | Oblique Therapeutics Ab | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer |
| MA47450A (fr) | 2017-02-07 | 2019-12-18 | Oblique Therapeutics Ab | Sulfinylpyridines et leur utilisation dans le traitement du cancer |
| BR112020016265A2 (pt) * | 2018-02-12 | 2020-12-15 | Cinda Pharma Ab | Inibidores da tioredoxina redutase para uso no tratamento de câncer |
| CR20210175A (es) | 2018-09-18 | 2021-06-01 | Nikang Therapeutics Inc | Derivados de anillo tricíclico condensado como inhibidores de la fosfatasa de homología a src 2 (shp2) |
| KR102812426B1 (ko) | 2018-10-29 | 2025-05-26 | 베링거 인겔하임 인터내셔날 게엠베하 | 피리디닐 설폰아미드 유도체, 약제학적 조성물 및 이의 용도 |
| US12213970B2 (en) | 2018-10-29 | 2025-02-04 | Boehringer Ingelheim International Gmbh | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof |
| KR102919383B1 (ko) | 2022-11-09 | 2026-01-28 | 한국생산기술연구원 | 정전압 압전기화학 분석 방법 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3064846D1 (en) * | 1979-12-19 | 1983-10-20 | Duphar Int Res | New nitrothiophenes, method of preparing the new compounds, as well as fungicidal and/or bactericidal compositions on the basis of the new compounds |
| AU543161B2 (en) | 1980-03-07 | 1985-04-04 | E.I. Du Pont De Nemours And Company | Pyrimidine or s.triazine derivatives |
| US4456469A (en) | 1980-03-07 | 1984-06-26 | E. I. Du Pont De Nemours And Company | Pyridyl sulfone herbicides |
| US4791127A (en) | 1985-10-07 | 1988-12-13 | Nippon Kayaku Kabushiki Kaisha | Alkanesulfonate derivatives and their use as insecticides, acaricides or nematicides |
| DE3812177A1 (de) | 1988-04-13 | 1989-10-26 | Bayer Ag | 2-phenylsulfinyl-nitro-pyridine, verfahren zu ihrer herstellung und ihre verwendung |
| WO1995029897A1 (en) | 1994-04-29 | 1995-11-09 | G.D. Searle & Co. | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS |
| WO1997008147A1 (de) | 1995-08-24 | 1997-03-06 | Basf Aktiengesellschaft | N-heterocyclische verbindungen, zwischenprodukte für ihre herstellung, sie enthaltende mittel und ihre verwendung zur bekämpfung von schadpilzen |
| DE19531148A1 (de) | 1995-08-24 | 1997-02-27 | Basf Ag | Fungizide Pyridin-2-yl-Derivate |
| WO1998054139A1 (de) | 1997-05-30 | 1998-12-03 | Basf Aktiengesellschaft | Verfahren zur herstellung substituierter thiopyridine |
| US6284923B1 (en) | 1997-08-22 | 2001-09-04 | Tularik Inc | Substituted benzene compounds as antiproliferative and cholesterol lowering action |
| AU9781098A (en) | 1997-10-02 | 1999-04-27 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6297239B1 (en) | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6191170B1 (en) | 1998-01-13 | 2001-02-20 | Tularik Inc. | Benzenesulfonamides and benzamides as therapeutic agents |
| EP0930302B1 (en) | 1998-01-16 | 2003-04-02 | F.Hoffmann-La Roche Ag | Benzosulfone derivatives |
| WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| AU2003211427A1 (en) | 2002-02-18 | 2003-09-04 | Ishihara Sangyo Kaisha, Ltd. | Pyridine derivatives or salts thereof and cytokine production inhibitors containing the same |
| US20030236287A1 (en) | 2002-05-03 | 2003-12-25 | Piotrowski David W. | Positive allosteric modulators of the nicotinic acetylcholine receptor |
| US7037902B2 (en) | 2002-07-03 | 2006-05-02 | Receptron, Inc. | Affinity small molecules for the EPO receptor |
| EP1651595A2 (en) | 2003-05-30 | 2006-05-03 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| PL1756084T3 (pl) | 2004-06-04 | 2009-06-30 | Arena Pharm Inc | Podstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu oraz profilaktyka i leczenie zaburzeń z metabolizmem związanych |
| US20060019967A1 (en) | 2004-07-21 | 2006-01-26 | Su-Ying Wu | SARS CoV main protease inhibitors |
| GB0426313D0 (en) | 2004-12-01 | 2005-01-05 | Merck Sharp & Dohme | Therapeutic agents |
| WO2006083692A2 (en) | 2005-01-28 | 2006-08-10 | Mount Sinai Schoool Of Medicine | Methods of identifying modulators of bromodomains |
| GB0504828D0 (en) | 2005-03-09 | 2005-04-13 | Merck Sharp & Dohme | Therapeutic agents |
| EP1976495A2 (en) | 2006-01-06 | 2008-10-08 | Aarhus Universitet | Compounds acting on the serotonin transporter |
| CA2647338A1 (en) | 2006-04-28 | 2007-11-08 | Avexa Limited | Integrase inhibitors-3 |
| US20090005422A1 (en) * | 2006-05-22 | 2009-01-01 | Thioredoxin Systems Ab | Bacterial thioredoxin reductase inhibitors and methods for use thereof |
| WO2009012283A1 (en) | 2007-07-17 | 2009-01-22 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| CN101723932B (zh) | 2008-10-31 | 2013-11-20 | 北京以岭生物工程技术有限公司 | 硝基吡啶乙烯亚胺化合物、其药物组合物及其制备方法和用途 |
| CA2763589A1 (en) * | 2009-05-28 | 2010-12-02 | President And Fellows Of Harvard College | N,n'-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation |
| NZ713361A (en) | 2009-08-17 | 2017-06-30 | Memorial Sloan Kettering Cancer Center | Heat shock protein binding compounds, compositions, and methods for making and using same |
| WO2011099502A1 (ja) | 2010-02-10 | 2011-08-18 | 公立大学法人横浜市立大学 | 神経選択的転写抑制因子NRSFに特異的に結合するmSin3B に結合する化合物の利用 |
| EP2536411A4 (en) * | 2010-02-18 | 2013-08-07 | Univ Princeton | HEMMER OF THE METABOLISM OF LOW-CHAIN AND VERY LOW-FATTYED FATTY ACIDS AS AN ANTIVIRUS ACTIVE SUBSTANCES WITH A WIDE SPECTRUM |
| CN102206172B (zh) | 2010-03-30 | 2015-02-25 | 中国医学科学院医药生物技术研究所 | 一组取代双芳基化合物及其制备方法和抗病毒应用 |
| EP2609089A1 (en) | 2010-08-27 | 2013-07-03 | Universität des Saarlandes | Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors |
| CN104220053B (zh) | 2012-02-10 | 2017-05-03 | 德克萨斯大学系统董事会 | cAMP直接活化交换蛋白(EPAC)的调节剂 |
| JP6393322B2 (ja) | 2013-07-10 | 2018-09-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規なキラル窒素−リン配位子及びアルケン類の不斉水素化のためのその使用 |
| CN104672214B (zh) | 2013-12-03 | 2019-04-12 | 上海翰森生物医药科技有限公司 | 具有alk抑制活性的化合物及其制备与用途 |
| CN105503827B (zh) | 2014-10-11 | 2019-09-24 | 上海翰森生物医药科技有限公司 | Egfr抑制剂及其制备方法和用途 |
| CN104987324B (zh) | 2015-06-04 | 2018-05-04 | 湖北生物医药产业技术研究院有限公司 | 作为alk抑制剂的嘧啶衍生物 |
| CN105085483B (zh) | 2015-06-04 | 2019-01-01 | 湖北生物医药产业技术研究院有限公司 | 激酶抑制剂及其应用 |
| GB201514021D0 (en) | 2015-08-07 | 2015-09-23 | Arner Elias Set Jeno | Novel Pyridines and their use in the treatment of cancer |
| MA47450A (fr) | 2017-02-07 | 2019-12-18 | Oblique Therapeutics Ab | Sulfinylpyridines et leur utilisation dans le traitement du cancer |
| CA3051539A1 (en) | 2017-02-07 | 2018-08-16 | Oblique Therapeutics Ab | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer |
| JP2020507625A (ja) | 2017-02-07 | 2020-03-12 | オブリーク セラピューティクス アーベー | ヘテロアリールスルホニル置換ピリジンおよび癌の治療におけるそれらの使用 |
-
2018
- 2018-02-07 AU AU2018218521A patent/AU2018218521C1/en not_active Ceased
- 2018-02-07 WO PCT/GB2018/050345 patent/WO2018146471A1/en not_active Ceased
- 2018-02-07 JP JP2019563698A patent/JP2020506244A/ja active Pending
- 2018-02-07 KR KR1020197024690A patent/KR20190115012A/ko not_active Ceased
- 2018-02-07 CA CA3051538A patent/CA3051538A1/en active Pending
- 2018-02-07 BR BR112019016233A patent/BR112019016233A2/pt not_active IP Right Cessation
- 2018-02-07 MA MA047452A patent/MA47452A/fr unknown
- 2018-02-07 EP EP18705719.5A patent/EP3580209A1/en not_active Withdrawn
- 2018-02-07 CN CN201880010203.5A patent/CN110382480A/zh active Pending
- 2018-02-07 US US16/483,961 patent/US11168069B2/en not_active Expired - Fee Related
- 2018-02-07 MX MX2019009354A patent/MX389800B/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020506244A5 (https=) | ||
| JP2020507625A5 (https=) | ||
| JP2020506970A5 (https=) | ||
| JP2020507624A5 (https=) | ||
| KR102386952B1 (ko) | 항암 및 항-증식 활성을 나타내는 n-아실-n'-(피리딘-2-일) 우레아 및 유사체 | |
| CN1065533C (zh) | 用作环氧合酶－2抑制剂的苯基杂环的制备方法 | |
| JP6317775B2 (ja) | ｃ−Ｍｅｔモジュレーターの使用方法 | |
| JP7848273B2 (ja) | ステロイド系誘導体モジュレーター、その製造方法及び応用 | |
| KR102194646B1 (ko) | 암 치료를 위한 피리미딘-2,4-다이아민 유도체 | |
| JP2021502993A5 (https=) | ||
| ES2858329T3 (es) | Compuestos moduladores del receptor de aril hidrocarburos (AhR) | |
| RU2019128063A (ru) | Углеводородсульфонилзамещенные пиридины и их применение при лечении рака | |
| JP2019514903A5 (https=) | ||
| WO2012102297A1 (ja) | ピラゾロピリジン誘導体、またはその薬理学的に許容される塩 | |
| JP2016504289A5 (https=) | ||
| HUP0104204A2 (hu) | COX-2 inhibítor hatású pirazolo-piridin-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| EA032469B1 (ru) | Новые трициклические соединения в качестве противораковых средств | |
| WO2008047831A1 (en) | Jak inhibitor | |
| TW201040178A (en) | Indolizine derivative and use thereof for medical purposes | |
| JPWO2008105515A1 (ja) | 新規なヒドロキサム酸誘導体 | |
| TW201838991A (zh) | 芳基烴受體(AhR)調節劑化合物 | |
| UA72611C2 (uk) | Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази | |
| RU2018107879A (ru) | Пиридины и их применение в лечении рака | |
| RU2019127896A (ru) | Сульфинилпиридины и их применение при лечении рака | |
| BR122020014933B1 (pt) | Compostos, composições farmacêuticas, benzenossulfonatos, forma a de ácido ptoluenossulfônico, forma b de ácido p-toluenssulfônico, forma i do ácido naftalenodissulfônico e forma ii do ácido naftalendissulfônico |